The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.

GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.

Developers of new ophthalmic products are thinking outside of the box. A raft of new gene therapies are progressing in the clinic, including a gene therapy paired with biomimetic goggles. Elsewhere, technology players are partnering with traditional biopharmaceutical companies and bringing algorithms, machine learning and microelectronics to bear on eye disorders and disease diagnostics.